Log in

Ultragenyx Pharmaceutical Stock Forecast, Price & News

+2.06 (+2.57 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $82.07
50-Day Range
MA: $82.24
52-Week Range
Now: $82.07
Volume257,182 shs
Average Volume511,502 shs
Market Capitalization$4.97 billion
P/E RatioN/A
Dividend YieldN/A
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Read More
Ultragenyx Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RARE



Sales & Book Value

Annual Sales$103.71 million
Book Value$11.32 per share


Net Income$-402,730,000.00
Net Margins-188.51%


Market Cap$4.97 billion
Next Earnings Date11/3/2020 (Estimated)
+2.06 (+2.57 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

How has Ultragenyx Pharmaceutical's stock price been impacted by COVID-19?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RARE shares have increased by 81.0% and is now trading at $82.07.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Ultragenyx Pharmaceutical?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ultragenyx Pharmaceutical

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Ultragenyx Pharmaceutical

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported ($0.82) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.56) by $0.74. The biopharmaceutical company earned $61.71 million during the quarter, compared to analyst estimates of $40.28 million. Ultragenyx Pharmaceutical had a negative net margin of 188.51% and a negative return on equity of 56.12%.
View Ultragenyx Pharmaceutical's earnings history

What price target have analysts set for RARE?

15 analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's shares. Their forecasts range from $64.00 to $99.00. On average, they anticipate Ultragenyx Pharmaceutical's share price to reach $82.38 in the next year. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical

Are investors shorting Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical saw a drop in short interest in the month of August. As of August 14th, there was short interest totaling 6,840,000 shares, a drop of 14.7% from the July 30th total of 8,020,000 shares. Based on an average trading volume of 450,900 shares, the days-to-cover ratio is presently 15.2 days. Approximately 12.2% of the company's stock are short sold.
View Ultragenyx Pharmaceutical's Short Interest

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), QUALCOMM (QCOM), TG Therapeutics (TGTX) and Crispr Therapeutics (CRSP).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.48%), Federated Hermes Inc. (6.73%), Macquarie Group Ltd. (2.52%), FMR LLC (2.38%), First Trust Advisors LP (1.96%) and Bank of New York Mellon Corp (1.25%). Company insiders that own Ultragenyx Pharmaceutical stock include Clay B Siegall, Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Barclays PLC, First Light Asset Management LLC, UBS Group AG, Hudson Bay Capital Management LP, Macquarie Group Ltd., Prudential Financial Inc., and CHI Advisors LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Clay B Siegall, Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga.
View insider buying and selling activity for Ultragenyx Pharmaceutical

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Vanguard Group Inc., Nuveen Asset Management LLC, New York State Common Retirement Fund, Federated Hermes Inc., Bank of New York Mellon Corp, TD Asset Management Inc., and Two Sigma Advisers LP.
View insider buying and selling activity for Ultragenyx Pharmaceutical

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $82.07.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $4.97 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.